Knight Announces Early Warning Filing Regarding Shares of Crescita

Executive Summary

• Knight Therapeutics Inc. reports the closing of a previously announced plan of arrangement whereby ClinActiv Holdings Inc. acquired all outstanding common shares of Crescita Therapeutics Inc.
• Knight Therapeutics, which previously held approximately 10.4% of Crescita’s shares, has fully divested its stake and is no longer an insider or subject to early warning reporting requirements.
• The transaction was completed for a cash consideration of $0.80 per share.

Key Details

• Transaction Type: Plan of arrangement (full acquisition)
• Target Company: Crescita Therapeutics Inc.
• Acquirer/Purchaser: ClinActiv Holdings Inc. (via wholly-owned subsidiary)
• Consideration: $0.80 cash per share for all issued and outstanding common shares
• Knight's Pre-Closing Position: Held 1,935,489 shares, representing approximately 10.4% of Crescita’s issued and outstanding shares
• Knight's Post-Closing Position: Holds 0 shares, ceased to be an insider, and is no longer subject to early warning reporting under Regulation 62-103
• Regulatory Context: Release disseminated to comply with Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues
• Crescita Head Office: 2805 Place Louis-R-Renaud, Laval, Québec, H7V 0A3
• Investor Contact: Samira Sakhia (President & CEO) and Arvind Utchanah (CFO) at Knight Therapeutics Inc. ([email protected])